Survival and lifetime costs associated with first-line bevacizumab use in older patients with metastatic colorectal cancer

Oncologist

Volumn 19, Issue 8, 2014, Pages 892-899

  Shankaran, Veena ^a,b,c   Mummy, David ^a   Koepl, Lisel ^a   Bansal, Aasthaa ^a   Mirick, Dana K ^b,c   Yu, Elaine ^d   Morlock, Rob ^d   Ogale, Sarika ^d   Ramsey, Scott D ^a,b,c  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d GENENTECH INC   (United States)

Author keywords

Bevacizumab; Clinical effectiveness; Elderly; Lifetime costs; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

AGED; ARTICLE; COHORT ANALYSIS; DRUG COST; DRUG EFFICACY; FEMALE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; SURVIVAL RATE; COLORECTAL NEOPLASMS; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH CARE COST; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; QUALITY ADJUSTED LIFE YEAR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; PROPORTIONAL HAZARDS MODELS; QUALITY-ADJUSTED LIFE YEARS;

EID: 84905514910     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2013-0209     Document Type: Article

References (46)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342.
2. Van Cutsem E, Rivera F, Berry S et al. Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: The BEAT study. Ann Oncol 2009; 20: 1842-1847.
3. Saltz LB, Clarke S, Díaz-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: A randomized phase III study. J Clin Oncol 2008; 26: 2013-2019.
4. Hochster HS, Hart LL, Ramanathan RK et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as firstline treatment of metastatic colorectal cancer: Results of the TREE Study. J Clin Oncol 2008; 26: 3523-3529.
5. Fuchs CS, Marshall J, Mitchell E et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007; 25: 4779-4786.
6. Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Updated results from the BICC-C study. J Clin Oncol 2008; 26: 689-690.
7. Ramsey S, Shankaran V. Managing the financial impact of cancer treatment: The role of clinical practice guidelines. J Natl Compr Canc Netw 2012; 10: 1037-1042.
8. Schrag D. Thepricetag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004; 351: 317-319.
9. Wong YN, Meropol NJ, Speier W et al. Cost implications of new treatments for advanced colorectal cancer. Cancer 2009; 115: 2081-2091.
10. Smith TJ, Hillner BE. Bending the cost curve in cancer care. N Engl J Med 2011; 364: 2060-2065.
11. Mariotto AB, Yabroff KR, Shao Y et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011; 103: 117-128.
12. Bach PB. Limits on Medicare's ability to control rising spending on cancer drugs. N Engl J Med 2009; 360: 626-633.
13. Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004; 22: 23-30.
14. Falcone A, Ricci S, Brunetti I et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676.
15. Cassidy J, Clarke S, Díaz-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-2012.
16. SEER stat facts sheets: Colon and rectum cancer. Available at http: //seer. cancer. gov/statfacts/ html/colorect. html. Accessed March 2013.
17. Kopetz S, Chang GJ, Overman MJ et al. Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 2009; 27: 3677-3683.
18. Meyerhardt JA, Li L, Sanoff HK et al. Effectiveness of bevacizumab with first-line combination chemotherapy for Medicare patients with stage IV colorectal cancer. J Clin Oncol 2012; 30: 608-615.
19. Kabbinavar FF, Hurwitz HI, Yi J et al. Addition of bevacizumab to fluorouracil-based first-line treatment of metastatic colorectal cancer: Pooled analysis of cohorts of older patients from two randomized clinical trials. J Clin Oncol 2009; 27: 199-205.
20. Cunningham D, Lang I, Marcuello E et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): An open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085.
21. Tappenden P, Jones R, Paisley S et al. The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales. Eur J Cancer 2007; 43: 2487-2494.
22. Lang K, Lines LM, Lee DW et al. Lifetime and treatment-phase costs associated with colorectal cancer: Evidence from SEER-Medicare data. Clin Gastroenterol Hepatol 2009; 7: 198-204.
23. Ambs A, Warren JL, Bellizzi KM et al. Overview of the SEER-Medicare Health Outcomes Survey linked dataset. Health Care Financ Rev 2008; 29: 5-21.
24. Surveillance, Epidemiology, and End Results program. Available at http: //seer. cancer. gov/. Accessed May 2011.
25. Warren JL, Klabunde CN, Schrag D et al. Overview of the SEER-Medicare data: Content, research applications, and generalizability to the United States elderly population. Med Care 2002; 40 (suppl): IV-3-IV-18.
26. American Joint Committee on Cancer. AJCC Cancer Staging Manual. 7th edNew York, NY: Springer, 2010.
27. SEER-Medicare linked database. Available at http: //healthservices. cancer. gov/seermedicare/. Accessed May 2011.
28. Klabunde CN, Legler JM, Warren JL et al. A refined comorbidity measurement algorithm for claims-based studies of breast, prostate, colorectal, and lung cancer patients. Ann Epidemiol 2007; 17: 584-590.
29. Klabunde CN, Potosky AL, Legler JM et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000; 53: 1258-1267.
30. Klabunde CN, Warren JL, Legler JM. Assessing comorbidity using claims data: An overview. Med Care 2002; 40(suppl): IV-26-IV-35.
31. Warren JL, Harlan LC, Fahey A et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002; 40(suppl): IV-55-IV-61.
32. Brown ML, Riley GF, Schussler N et al. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care 2002; 40(suppl): IV-104-IV-117.
33. Lin DY. Proportional means regression for censored medical costs. Biometrics 2000; 56: 775-778.
34. Lin DY, Feuer EJ, Etzioni R et al. Estimating medicalcosts from incomplete follow-up data. Biometrics 1997; 53: 419-434.
35. ASP drug pricing files October 2013 update. Available at http: //www. cms. gov/Medicare/MedicareFee-for-Service-Part-B-Drugs/McrPartBDrugAvg SalesPrice/2013ASPFiles. html. Accessed March 2013.
36. Weinstein MC, Siegel JE, Gold MR et al. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA 1996; 276: 1253-1258.
37. Goulart B, Ramsey S. A trial-based assessment of the cost-utility of bevacizumab and chemotherapy versus chemotherapy alone for advanced nonsmall cell lung cancer. Value Health 2011; 14: 836-845.
38. Ramsey SD, Andersen MR, Etzioni R et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-1303.
39. O'Neill CB, Atoria CL, O'Reilly EM et al. Costs and trends in pancreatic cancer treatment. Cancer 2012; 118: 5132-5139.
40. Song X, Zhao Z, Barber B et al. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011; 14: 1-9.
41. Stokes ME, Black L, Benedict A et al. Long-term medical-care costs related to prostate cancer: Estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010; 13: 278-284.
42. Stokes ME, Ishak J, Proskorovsky I et al. Lifetime economic burden of prostate cancer. BMC Health Serv Res 2011; 11: 349.
43. Warren JL, Yabroff KR, Meekins A et al. Evaluation of trends in the cost of initial cancer treatment. J Natl Cancer Inst 2008; 100: 888-897.
44. White LA, Menzin J, Korn JR et al. Medical care costs and survival associated with hepatocellular carcinoma among the elderly. Clin Gastroenterol Hepatol 2012; 10: 547-554.
45. Ramsey SD, Howlader N, Etzioni RD et al. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: Evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004; 22: 4971-4978.
46. Yang H, Yu AP, Wu EQ et al. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer. J Med Econ 2011; 14: 542-552.